CD274 and Miyoshi myopathy: In fact, in vitro experiments have also demonstrated that PD-1/PD-L1 inhibitors directly enhance NK cell- and T cell-mediated immune responses against MM, and lenalidomide (immunomodulator) significantly enhanced such immune responses (199).